[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369798-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369798-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","atr-chk1-axis-inhibitors-in-gastric-cancer-treatment","ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment","","Gastric cancer remains a major global health challenge, with uneven incidence and mortality and poor prognosis for many patients despite improvements in screening and early detection. DNA damage response research has identified actionable molecular vulnerabilities in gastric tumors, including frequent TP53 mutations, ARID1A loss, ATM deficiency, and oncogene-driven replication stress. These changes create strong dependency on the ATR–CHK1 axis for tumor survival. This review integrates clinical and preclinical evidence for ATR and CHK1 inhibitors, emphasizing synthetic lethality, immune modulation, resistance mechanisms, and biomarker-guided patient selection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/atr-chk1-axis-inhibitors-in-gastric-cancer-treatment/369798/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/atr-chk1-axis-inhibitors-in-gastric-cancer-treatment/369798.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are ATR and CHK1 inhibitors considered promising for gastric cancer?","Question",{"text":63,"@type":64},"Gastric tumors often show DNA damage response defects and replication stress that make them dependent on the ATR–CHK1 axis, supporting ATR and CHK1 inhibition as a therapeutic strategy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What therapeutic themes does the review emphasize for ATR–CHK1 targeting?",{"text":68,"@type":64},"The review highlights synthetic lethality, immune modulation, combination possibilities with chemotherapy, radiotherapy, or immune checkpoint blockade, and approaches to address resistance and treatment failure.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the review suggest improving clinical effectiveness and safety?",{"text":72,"@type":64},"It emphasizes biomarker-guided patient selection, adaptive dosing to reduce toxicity, and refined pharmacodynamic monitoring to improve therapeutic precision.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369798,1790207265,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment  \nMateusz Kciuk 1, *, Renata Gruszka 1, Marta Aleksandrowicz 2, Agnieszka ´Sliwi ´nska 3 and Renata Kontek 1  \nAcademic Editor: Alain Couvineau  \nReceived: 21 July 2025  \nRevised: 4 August 2025  \nAccepted: 8 August 2025  \nPublished: 9 August 2025  \nCitation: Kciuk, M.; Gruszka, R.; Aleksandrowicz, M.; ´Sliwi ´nska, A.;  \nKontek, R. ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment. Int. J. Mol. Sci. 2025, 26, 7709. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26167709](doi.org/10.3390/ijms26167709)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland; [renata.gruszka@biol.uni.lodz.pl](renata.gruszka@biol.uni.lodz.pl) (R.G.); [renata.kontek@biol.uni.lodz.pl](renata.kontek@biol.uni.lodz.pl) (R.K.)  \n2 Laboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 A. Pawi ´nskiego Street, 02-106 Warsaw, Poland; [maleksandrowicz@imdik.pan.pl](maleksandrowicz@imdik.pan.pl)  \n[3](3 Department of Nucleic Acid Biochemistry)[ Department of Nucleic Acid Biochemistry](3 Department of Nucleic Acid Biochemistry), [Medical University of Lodz](Medical University of Lodz), [Pomorska 251](Pomorska 251), [92-213 Lodz](92-213 Lodz), [Poland](Poland); [agnieszka.sliwinska@umed.lodz.pl](agnieszka.sliwinska@umed.lodz.pl)  \n* [Correspondence: mateusz.kciuk@biol.uni.lodz.pl](Correspondence: mateusz.kciuk@biol.uni.lodz.pl)  \nAbstract  \nGastric cancer remains a significant global health challenge, with regional and demographic disparities in incidence, mortality, and treatment outcomes. Despite advances in screening and early detection, prognosis remains poor for many patients, particularly those with advanced disease. Recent insights into DNA damage response pathways have uncovered critical molecular vulnerabilities in gastric tumors, including frequent TP53 mutations, ARID1A loss, ATM deficiency, and oncogene-driven replication stress, which render these cancers highly dependent on the ATR–CHK1 axis for survival. This review synthesizes current clinical and preclinical evidence on ATR and CHK1 inhibitors as therapeutic strategies in gastric cancer. Emphasis is placed on synthetic lethality, immune modulation, and the potential for combination regimens with chemotherapy, radiotherapy, or immune checkpoint blockade. Mechanisms of resistance, including transcription-associated replication stress modulation and bypass signaling networks, are discussed, alongside strategies to predict and overcome therapeutic failure. The review also highlights the importance of biomarkerguided patient selection, adaptive dosing to reduce toxicity, and refined pharmacodynamic monitoring to enhance therapeutic precision. Collectively, these insights support the rational integration of ATR–CHK1 inhibitors into clinical protocols for biomarker-defined gastric cancer subsets and underscore their promise  \nKeywords: gastric cancer; ATR–CHK1 inhibitors; DNA damage response; replication stress; synthetic lethality; TP53 mutation; ARID1A loss; immune modulation; treatment resistance; biomarker-guided therapy  \n1. Introduction  \nGastric cancer remains a major global health burden, although its epidemiological landscape has shifted significantly over recent decades. Once the second most common cancer worldwide in 1990, gastric cancer ranked fifth in both incidence and mortality in 2022, according to estimates by the International Agency for Research on Cancer (IARC) . Despite a steady","cbCaipV4vXLjlBlY","https://ap.wps.com/l/cbCaipV4vXLjlBlY","pdf",1613840,33,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why are ATR and CHK1 inhibitors considered promising for gastric cancer?\",\"answer\":\"Gastric tumors often show DNA damage response defects and replication stress that make them dependent on the ATR–CHK1 axis, supporting ATR and CHK1 inhibition as a therapeutic strategy.\"},{\"question\":\"What therapeutic themes does the review emphasize for ATR–CHK1 targeting?\",\"answer\":\"The review highlights synthetic lethality, immune modulation, combination possibilities with chemotherapy, radiotherapy, or immune checkpoint blockade, and approaches to address resistance and treatment failure.\"},{\"question\":\"How does the review suggest improving clinical effectiveness and safety?\",\"answer\":\"It emphasizes biomarker-guided patient selection, adaptive dosing to reduce toxicity, and refined pharmacodynamic monitoring to improve therapeutic precision.\"}]","ATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment | PDF",1790184599,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32892833ea746563032e4b595b7c7f34.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d2b125717fe5d0b279771ad61a6ce0d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50aec6ba1b92b37f5bd414f65a4ce98a.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5305eeba7881a2a2788a2213f279d62.webp",980,1385]